Healthcare new Lows: Infinity Pharmaceuticals (NASDAQ:INFI), Spherix (NASDAQ:SPEX), BioTime (NYSEMKT:BTX), MELA Sciences (NASDAQ:MELA)

Infinity Pharmaceuticals (NASDAQ:INFI) has been selected by InvestorsObserver analysts as a stock that is a strong candidate for a new covered call. Selling the May $12.00 call while simultaneously buying INFI stock for $11.89 will result in a new position with a break-even point around $10.79. At that price, this position has a target return of 11.2 %. This trade has 9.3 % downside protection, while still providing a 11.2 % return in 46 days as long as INFI is above $12.00 on 5/17/2014. For comparison purposes only, this Infinity Pharmaceuticals covered call targets an annualized return rate of 88.9 %. Infinity Pharmaceuticals Inc. (NASDAQ:INFI) shares after opening at $11.07 moved to $11.15 on last trade day and at the end of the day closed at $10.62. Company price to cash ratio as 2.40. Infinity Pharmaceuticals Inc. (NASDAQ:INFI) showed a negative weekly performance of 11.65%.

Spherix Inc(NASDAQ:SPEX) has since lost some ground on the stock market, largely due to a dud volume-based transactions at the end of trading session. The company has reported lesser on the stock prices by 12.45% , closing at $3.00 per share. The volumes trading were at 1.31 million shares. Spherix Inc (NASDAQ:SPEX) shares fell 3.19% in last trading session and ended the day on $2.73. Spherix Inc (NASDAQ:SPEX) return on equity ratio is recorded as -550.40% and its return on assets is -373.10%. Spherix Inc (NASDAQ:SPEX) yearly performance is -62.76%.

BioTime, Inc. (NYSEMKT: BTX) shares traded in the range of $3.01 to $3.29 Monday before settling to close at $3.29, an increase of 5.79 percent. The stock appears to be facing some resistance at the $3.32 and $3.50 levels with some support at $3.26. Shares of BioTime are down approximately 8.0 percent year-to-date. BioTime, Inc. (NYSEMKT:BTX) shares moved down 4.49% in last trading session and was closed at $2.98, while trading in range of $ 2.95 – 3.18. BioTime, Inc. (NYSEMKT:BTX) year to date (YTD) performance is -17.22%.

MELA Sciences, Inc, (the “Company”), developer of MelaFind , an FDA approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, announced financial results for the fourth quarter and year ended December 31, 2013. MELA Sciences Inc (NASDAQ:MELA) weekly performance is -11.11%. On last trading day company shares ended up $0.560. MELA Sciences Inc (NASDAQ:MELA) distance from 50-day simple moving average (SMA50) is -19.82%. Analysts mean target Price for the company is $1.00.